When.com Web Search

  1. Ads

    related to: ttr amyloid polyneuropathy

Search results

  1. Results From The WOW.Com Content Network
  2. Familial amyloid polyneuropathy - Wikipedia

    en.wikipedia.org/.../Familial_amyloid_polyneuropathy

    Familial amyloid polyneuropathy, also called transthyretin-related hereditary amyloidosis, transthyretin amyloidosis abbreviated also as ATTR (hereditary form), or Corino de Andrade's disease, [1] is an autosomal dominant [2] neurodegenerative disease.

  3. Familial amyloid neuropathy - Wikipedia

    en.wikipedia.org/wiki/Familial_amyloid_neuropathy

    The familial amyloid neuropathies (or familial amyloidotic neuropathies, neuropathic heredofamilial amyloidosis, familial amyloid polyneuropathy) are a rare group of autosomal dominant diseases wherein the autonomic nervous system and/or other nerves are compromised by protein aggregation and/or amyloid fibril formation. [1] [2] [3]

  4. Eplontersen - Wikipedia

    en.wikipedia.org/wiki/Eplontersen

    Eplontersen, sold under the brand name Wainua, is a medication used for the treatment of transthyretin-mediated amyloidosis. [3] It is a transthyretin-directed antisense oligonucleotide. [3] It was developed to treat hereditary transthyretin amyloidosis by Ionis Pharmaceuticals and AstraZeneca. [4] [5] [6] [7]

  5. Transthyretin - Wikipedia

    en.wikipedia.org/wiki/Transthyretin

    TTR misfolding and aggregation is known to be associated with amyloid diseases [13] including wild-type transthyretin amyloidosis, [14] hereditary transthyretin amyloidosis, [15] familial amyloid polyneuropathy (FAP), [16] [17] and familial amyloid cardiomyopathy (FAC). [18] TTR tetramer dissociation is known to be rate-limiting for amyloid ...

  6. Amyloidosis - Wikipedia

    en.wikipedia.org/wiki/Amyloidosis

    Inotersen blocks gene expression of both wild-type and mutant TTR, reducing amyloid precursor. Moderate-certainty evidence suggests that it mitigates worsening of peripheral neuropathy. Long-term efficacy and safety of inotersen use in people with mutant TTR-related amyloidosis is still be evaluated in a phase-III clinical trial as of 2021.

  7. Tafamidis - Wikipedia

    en.wikipedia.org/wiki/Tafamidis

    Tafamidis was approved in the European Union in 2011 for the treatment of transthyretin amyloidosis with polyneuropathy, and in Japan in 2013. [6] [17] In the United States, it was rejected for the treatment of transthyretin amyloidosis with polyneuropathy because the Food and Drug Administration saw insufficient evidence for its efficacy. [20] [7]

  1. Ads

    related to: ttr amyloid polyneuropathy